U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Center for Drug Evaluation and Research | CDER
  5. Division of Oncology 2 (DO2)
  1. Center for Drug Evaluation and Research | CDER

Division of Oncology 2 (DO2)

The Office of New Drugs is undergoing a reorganization. This site may be updated in the near future. Please check back often. For more information, please visit Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality.

The Division of Oncology 2 (DO2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: Thoracic Head & neck, Neuro-oncology Rare cancers, Pediatric solid tumors.

Management Team

Division Director (Acting), Harpreet Singh, MD
Deputy Director: Vacant

Office of Regulatory Operations – Oncologic Diseases (ORO-OD) for DO2

Chief Project Management Staff: Monica Hughes, MS

Mailing Address:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Oncology 2 (DO2)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Phone: (301) 796-2320
Fax: (301) 796-9849

Resources For You

Back to Top